Reverse white-coat effect as an independent risk for microalbuminuria in treated hypertensive patients

Nephrology Dialysis Transplantation

Volumn 22, Issue 3, 2007, Pages 911-916

  Kato, Toako ^a   Horio, Takeshi ^a   Tomiyama, Mari ^a   Kamide, Kei ^a   Nakamura, Satoko ^a   Yoshihara, Fumiki ^a   Nakata, Hiroto ^a   Nakahama, Hajime ^a   Kawano, Yuhei ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Ambulatory blood pressure monitoring; Hypertension; Microalbuminuria

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; CREATININE URINE LEVEL; DISEASE ASSOCIATION; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTIVARIATE ANALYSIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RETROSPECTIVE STUDY; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; WHITE COAT HYPERTENSION;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CREATININE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INCIDENCE; JAPAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 33847673502     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl642     Document Type: Article

References (24)

1. Pickering TG, Harshfield GA, Devereux RB, Laragh JH. What is the role of ambulatory blood pressure monitoring in the management of hypertensive patients? Hypertension 1985; 7: 171-177
2. Schillaci G, Verdecchia P, Sacchi N et al. Clinical relevance of office underestimation of usual blood pressure in treated hypertension. Am J Hypertens 2000; 13: 523-528
3. Cuspidi C, Meani S, Fusi V et al. Isolated ambulatory hypertension and changes in target organ damage in treated hypertensive patients. J Hum Hypertens 2005; 19: 471-477
4. Perloff D, Sokolow M, Cowan R. The prognostic value of ambulatory blood pressures. JAMA 1983; 249: 2792-2798
5. Staessen JA, Thijs L, Fagard R et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999; 282: 539-546
6. Verdecchia P, Reboldi G, Porcellati C et al. Risk of cardiovascular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subjects. J Am Coll Cardiol 2002; 39: 878-885
7. Palatini P, Mormino P, Santonastaso M et al. Target-organ damage in stage I hypertensive subjects with white coat and sustained hypertension: Results from the HARVEST study. Hypertension 1998; 31: 57-63
8. Khattar RS, Senior R, Lahiri A. Cardiovascular outcome in white-coat versus sustained mild hypertension: A 10-year follow-up study. Circulation 1998; 98: 1892-1897
9. Pickering TG, Davidson K, Gerin W, Schwartz JE. Masked hypertension. Hypertension 2002; 40: 795-796
10. Wing LMH, Brown MA, Beilin LJ, Ryan P, Reid CM. 'Reverse white-coat hypertension' in older hypertensives. J Hypertens 2002; 20: 639-644
11. Bombelli M, Sega R, Facchetti R et al. Prevalence and clinical significance of a greater ambulatory versus office blood pressure ('reversed white coat' condition) in a general population. J Hypertens 2005; 23: 513-520
12. Clement DL, De Buyzere ML, De Bacquer DA et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003; 348: 2407-2415
13. Bobrie G, Chatellier G, Genes N et al. Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004; 291: 1342-1349
14. Bigazzi R, Bianchi S. Microalbuminuria as a marker of cardiovascular and renal disease in essential hypertension. Nephrol Dial Transplant 1995; 10 [Suppl 6]: 10-14
15. Pontremoli R, Leoncini G, Ravera M et al. Microalbuminuria, cardiovascular, and renal risk in primary hypertension. J Am Soc Nephrol 2002; 13 [Suppl 3]: S169-S172
16. Kawano Y, Matsuoka H, Takishita S, Omae T. Effects of magnesium supplementation in hypertensive patients: Assessment by office, home, and ambulatory blood pressures. Hypertension 1998; 32: 260-265
17. Imai Y, Sasaki S, Minami N et al. The accuracy and performance of the A&D TM 2421, a new ambulatory blood pressure monitoring device based on the cuff-oscillometric and the Korotkoff sound technique. Am J Hypertens 1992; 5: 719-726
18. Myers MG, Oh PI, Reeves RA, Joyner CD. Prevalence of white coat effect in treated hypertensive patients in the community. Am J Hypertens 1995; 8: 591-597
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
20. Liu JE, Roman MJ, Pini R, Schwartz JE, Pickering TG, Devereux RB. Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure. Ann Intern Med 1999; 131: 564-572
21. Sega R, Trocino G, Lanzarotti A et al. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: Data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study). Circulation 2001; 104: 1385-1392
22. Björklund K, Lind L, Zethelius B, Andrén B, Lithell H. Isolated ambulatory hypertension predicts cardiovascular morbidity in elderly men. Circulation 2003; 107: 1297-1302
23. Ohkubo T, Kikuya M, Metoki H et al. Prognosis of "masked" hypertension and "white-coat" hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll Cardiol 2005; 46: 508-515
24. Pierdomenico SD, Lapenna D, Bucci A et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 2005; 18: 1422-1428